Pharmaceutical Executive-05-01-2019

Private equity investment and venture capital have long spurred R&D efforts for hard-to-treat conditions. Joining the mix of late has been impact investing and the opportunities for the socially-conscious to influence drug development-and reap potential benefits in health outcomes and financial return.

European industry fights over every inch on comparative drug pricing initiative.

Op-Ed: The best way to capitalize on the potential revenue influx from enterprise-level drug adherence programs is to create room at the executive table for a Chief Adherence Officer.

Preserving positive ROI amid healthcare’s innovation explosion.

Pair of interviews spotlight the changing dynamics for C-suite business managers in two contrasting life sciences settings-big, established pharma and small, aggressive biotech.

With conference season in high gear, here's the lowdown on our content highlights so far from the event circuit and what to expect on horizon.

Findings support the belief that today’s pharma finance teams should be engaged across all functional areas, including regulatory, supply chain, manufacturing, and commercial. What does that mean for current and future CFOs in the industry?

New leadership faces a host of complex initiatives to promote innovation and protect public health.

Steps for startups in tapping non-dilutive financing options.

Weighing the benefits of a deeper quantitative review for pharma.

Click the title above to open the Pharmaceutical Executive May 2019 issue in an interactive PDF format.

Following its economic rise in recent decades, driven by innovation across a wide variety of powerhouse industries, South Korea is setting its sights on the next generation of technological growth-including new strategies to globalize and industrialize the nation’s pharmaceutical and healthcare sector.